Cornelius Group continues with its focus on pharmaceutical r&d

Published: 30-Jun-2011

Cornelius Group is continuing with the expansion of its pharmaceutical ingredients offer to fully support innovation in oral dosage forms

Cornelius Group, the leading pan European supply chain management company, is continuing with the expansion of its pharmaceutical ingredients offer to fully support innovation in oral dosage forms. Cornelius' approach has always been to collaborate with the leading global producers of innovative materials to provide complete confidence in the quality, and minimise risk, in the development process.

Cafosa's directly compressible medicated gum bases are a mix of excipients that when mixed with active, lubricant and flavour can be pressed into tablets on a conventional tablet press. This novel dosage form supports efficient and cost-effective new product introductions and will be included in the next edition of the EP.

Huber's RXCipient FM100 works in conjunction with superdisintegrants to transform conventional tablets into an orally dispersible form, delivering actives to the body quicker and supporting dysphagic patients.

Suheung is a global leader in hard shell capsule manufacture; its patented locking 'EMBO' mechanism reduces wastage, downtime and costs by preventing excessive joining of the cap and body during the manufacturing stage. When filled, the Embo Caps are resistant to any contingent forces separating the cap and body.

Cornelius offers tangible benefits to pharmaceutical development and manufacturing companies - supply risk assessment, extensive speciality product range and supplier auditing for complete confidence in its ingredients. For more details please call +44 1279 714300, or visit www.cornelius.co.uk


You may also like